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Abstract. Increased translocation of intestinal bacteria is a hallmark
of chronic liver disease and contributes to hepatic inﬂammation and
ﬁbrosis. Here we tested the hypothesis that the intestinal microbiota
and Toll-like receptors (TLRs) promote hepatocellular carcinoma
(HCC), a long-term consequence of chronic liver injury, inﬂamma-
tion, and ﬁbrosis. Hepatocarcinogenesis in chronically injured livers
depended on the intestinal microbiota and TLR4 activation in non-
bone-marrow-derived resident liver cells. TLR4 and the intestinal
microbiota were not required for HCC initiation but for HCC promo-
tion, mediating increased proliferation, expression of the hepatomi-
togen epiregulin, and prevention of apoptosis. Gut sterilization
restricted to late stages of hepatocarcinogenesis reduced HCC, sug-
gesting that the intestinal microbiota and TLR4 represent therapeutic
targets for HCC prevention in advanced liver disease.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Chronic inﬂammation of the liver is a well-recognized risk factor
for carcinogenesis, 80% of all cases of hepatocellular carcinoma
(HCC) being associated with cirrhosis or ﬁbrosis, diseases charac-
terized by persistent cycles of liver injury, inﬂammation, and
compensatory hepatocyte proliferation. Accumulating evidence
supports the idea that persistent inﬂammation leads to HCC. In
recent years, a number of studies have been dedicated to the
characterization of signal transducing mediators that connect
liver inﬂammation to carcinogenesis [1]. Recent studies have
focused on the possible pro-inﬂammatory pro-tumor role of lipo-Journal of Hepatology 20
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E-mail address: nicolas.moniaux@inserm.fr (N. Moniaux).polysaccharide (LPS), a pathogen-associated molecular pattern
(PAMP) of the gut-liver axis. Indeed, high levels of LPS occur in
patients with cirrhosis because of an increase in intestinal muco-
sal permeability and bacterial translocation (for review [2]). This
activates the NF-jB pathway, produces proinﬂammatory cyto-
kines (TNF-a, IL-6, and IL-1) and leads to liver inﬂammatory
and oxidative damage. As LPS acts as a potent ligand for activa-
tion of the innate immunity Toll like receptor 4 (TLR4), experi-
mental approaches have been based on alterations of intestinal
LPS balance or TLR4 activity.
A ﬁrst comprehensive study of the role of gut-derived LPS in
hepatocarcinogenesis was published by Yu et al. in 2010 [3]. In
that study, HCC was induced by diethylnitrosamine (DEN)
through ten weekly injections in Sprague-Dawley rats or a single
injection in C57Bl/6 mice. Yu et al. found that gut sterilization
and TLR4 depletion decreased HCC tumor incidence and growth
and concluded that LPS accumulation was a promoter of HCC in
DEN-treated rodents [3].
The importance of the LPS-TLR4 pathway in hepatocarcinogen-
esis has recently been more ﬁrmly established by a very extensive
study by Dapito et al. [4]. In that study, HCCwas induced in several
genetically different mouse lines following protocols consisting in
an initial injection of DEN followed by a choline-deﬁcient diet or
multiple carbon tetrachloride (CCl4) injections or thioacetamide
injections. Dapito et al. found that inactivating TLR4 had no effect
on HCC tumor incidence, but signiﬁcantly reduced tumor number
and size [4]. A HCC slowdown was observed after DEN/CCl4 intox-
ication in wild type mice, whose gut was germ-free or had been
sterilized with antibiotics. By contrast, continuous administration
of low doses of LPS increased tumor number and size in conven-
tional wild type mice intoxicated with DEN/CCl4 [4]. Dapito et
al. concluded that the gut microbiota and LPS-TLR4 pathway play
a role in HCC promotion in chronically injured livers. On the other
hand, they found no effect of the LPS-TLR4 pathway on HCC initi-
ation, at variance with Yu et al. conclusions. Beyond the differ-
ences in experimental methods (mouse lines, animal care, and
liver injury) between the two studies, this discrepancy could point
to other unrecognized gut PAMPs, in addition to LPS, contributing
to carcinogenesis in inﬂammatory livers.
From the standpoint of molecular and cellular mechanisms, an
important ﬁnding of Dapito et al. is that the tumor-promoting
effect of TLR4 inﬂammatory signaling originates from resident
liver cells (hepatic stellate cells and hepatocytes) and not bone-
marrow-derived cells such as macrophages [4]. NF-jB p65 nuclear
translocation was found in hepatic stellate cells and hepatocytes,
suggesting that both cell types play a role in the promotion of13 vol. 58 j 385–387
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Fig. 1. Hypothetic diagram of HCC promotion by the LPS/TLR4 pathway. The progression of HCC depends on the balance between TRL4-induced proliferative, pro-
survival, and apoptotic signals in chronically injured hepatocytes. The chronic inﬂamed liver is associated with intestinal dysbiosis, gut permeability changes, and PAMP
(LPS) translocation to the liver. The TLR4 signaling is activated by LPS in hepatic stellate cells and hepatocytes, resulting in extracellular matrix (ECM) remodeling,
ﬁbrogenesis, and secretion of the epiregulin growth factor, which triggers tumor hepatocyte proliferation. The inﬂammatory liver signals to the gut, maintaining, or
amplifying, intestinal dysbiosis.
International HepatologyDEN/CCl4-induced HCC. These results differ from those of Yu et
al., and others, who found that Küpffer cells were the main target
of LPS/TLR4 signals, leading to TNFa- and IL6-dependent hepato-
cyte compensatory proliferation and reduction of oxidative and
apoptotic stress [3]. The fact that different authors identify differ-
ent cell targets for LPS in injured livers is probably not self-con-
tradictory. It may simply point to the complexity of the
intercellular dialog between different chronically injured liver
cell types aroused by inﬂammatory signals originating from gut
microbiota and eventually leading to HCC. In addition, Dapito et
al. reported that the LPS/TLR4 pathway upregulates the epiregu-
lin hepatomitogen, an epidermal growth factor (EGF) family
member leading to EGFR and HER2 activation during the ﬁrst
stages of DEN/CCl4 carcinogenesis, whereas it reduces hepatocyte
apoptosis by NF-jB nuclear translocation during the late stages
of hepatocarcinogenesis [4] (Fig. 1).
Other studies showed that acute [5] and chronic [6,7] liver dis-
eases had also an impact on gut homeostasis and led to dysbiosis
and gut barrier permeability, exacerbating viral and chemically
induced HCC incidence via NFjB pathway activation [8,9]. Dapito
et al. suggested that antibiotic-induced gut sterilization could pre-
vent HCC in patients with chronic liver injury [4]. Such a preven-
tive management of cirrhotic patients would require a life-time
administration of antibiotic. Counteracting side effects of dysbio-
sis by probiotic administration or bacteria infusion might be an
alternative to antibiotic therapy. In fact, approaches based on
gut microbiota manipulation have already been evaluated for
other dysbiosis-associated disorders. Vrieze et al. performed a
double-blind randomized control trial, which showed that386 Journal of Hepatology 201bacterial transplantation by lean-donor feces infusion in patients
with metabolic syndrome led to improvement of hepatic and per-
ipheral insulin resistance [10]. It would be interesting to evaluate
this type of clinical setting in patients at high risk to develop HCC.Conﬂict of interest
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